Therapy Areas: Devices
Nimbus Therapeutics Closes USD 125m Private Financing
12 September 2022 - - US-based clinical-stage company Nimbus Therapeutics has closed a USD 125m private financing, the company said.

The round involves participation from new investors Bain Capital Life Sciences and SV Health Investors, along with existing investors including Access biotechnology, Atlas Venture, BVF Partners L.P., Bill Gates, Lightstone Ventures, Pfizer Ventures, RA Capital Management and SR One.

The financing will support the completion of the ongoing Phase 2b clinical trials of NDI-034858, Nimbus' oral allosteric tyrosine kinase 2 inhibitor, in moderate-to-severe plaque psoriasis and active psoriatic arthritis, the initiation of psoriasis Phase 3 trials, as well as the initiation of additional Phase 2b clinical trials of NDI-034858 in other autoimmune indications, including inflammatory bowel disease and lupus.

The financing also will support the ongoing Phase 1/2 clinical trials of NDI-101150, Nimbus' hematopoietic progenitor kinase 1 inhibitor, in patients with solid tumors, as well as preclinical development of programs targeting Casitas B-lineage lymphoma b (Cbl-b) and Werner syndrome helicase, along with ongoing discovery efforts across a range of targets.

In addition to this financing, Nimbus has recently appointed Gorjan Hrustanovic, Ph.D., Managing director of BVF Partners, L.P., to its board of directors.

Dr. Hrustanovic serves on a number of other public and private biotech boards, and trained in cancer biology and translational medicine at the University of California, San Francisco.

Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases.

Nimbus combines computational technologies with a tailored array of machine learning-based predictive modeling approaches.

Nimbus has designed, discovered and developed a diverse portfolio of clinical and preclinical programs focused on inflammatory and autoimmune disorders, cancer and metabolic diseases, including three internally discovered compounds that have advanced into clinical trials. Nimbus is headquartered in Cambridge, Massachusetts.

SV Health Investors is a healthcare fund manager committed to investing in tomorrow's healthcare breakthroughs.

The SV family of funds invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities.

With over USD 2.5bn in assets under management and a transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans.

Since its founding in 1993, SV has invested in more than 200 companies with more than 90 of these having achieved successful acquisitions or IPOs.

Bain Capital Life Sciences invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies.